Irinotecan Phares (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted inside cancer cells to the active metabolite SN‑38, which inhibits topoisomerase I. This prevents the re‑ligation of single‑strand DNA breaks, leading to accumulation of DNA damage and ultimately cell death in rapidly dividing tumor cells.

The dosing regimen for Irinotecan Phares is determined by the prescribing oncologist based on the patient’s clinical condition, body surface area, and treatment protocol. Specific dose amounts and schedules are not disclosed here.

Irinotecan is classified as contraindicated in pregnancy because it may cause fetal harm. Limited data exist for breastfeeding, and the drug is generally not recommended as it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the Irinotecan Phares product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

The primary alternative in colorectal cancer regimens is oxaliplatin, a platinum‑based agent. While oxaliplatin causes DNA cross‑linking, Irinotecan inhibits topoisomerase I. Both are effective, but they differ in toxicity profiles; Irinotecan is more associated with diarrhea and neutropenia, whereas oxaliplatin commonly causes peripheral neuropathy.

Irinotecan Phares should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and do not freeze or shake the product. If temporary storage at controlled room temperature is unavoidable, limit exposure to no more than 24 hours.

The product is supplied as a sterile injectable solution for intravenous infusion. Administration is performed by qualified healthcare professionals, usually over 30‑90 minutes, following institutional protocols and pre‑medication guidelines to mitigate infusion‑related reactions.

The most critical adverse events include severe neutropenia with fever, life‑threatening diarrhea (colitis), and hypersensitivity reactions that can progress to anaphylaxis. Prompt recognition and medical intervention are essential to manage these risks.

Patients with known hypersensitivity to irinotecan or any component of the formulation, those with unresolved bowel obstruction, and individuals with severe hepatic impairment should avoid Irinotecan Phares. Additionally, it is contraindicated during pregnancy.